Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology
- PMID: 22279515
- PMCID: PMC3264661
- DOI: 10.2174/187569211794728850
Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology
Conflict of interest statement
None declared/applicable.
Figures


Similar articles
-
Role of pharmacoproteomics in the development of personalized medicine.Pharmacogenomics. 2004 Apr;5(3):331-6. doi: 10.1517/phgs.5.3.331.29830. Pharmacogenomics. 2004. PMID: 15102547 Review.
-
Role of Proteomics in the Development of Personalized Medicine.Adv Protein Chem Struct Biol. 2016;102:41-52. doi: 10.1016/bs.apcsb.2015.09.002. Epub 2015 Nov 11. Adv Protein Chem Struct Biol. 2016. PMID: 26827601 Review.
-
Opportunities for pharmacoproteomics in biomarker discovery.Proteomics. 2023 Apr;23(7-8):e2200031. doi: 10.1002/pmic.202200031. Epub 2022 Sep 22. Proteomics. 2023. PMID: 36086888 Review.
-
Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).OMICS. 2014 Apr;18(4):211-21. doi: 10.1089/omi.2014.0029. Epub 2014 Mar 20. OMICS. 2014. PMID: 24649998 Free PMC article.
-
Synthetic biology and the prospects for responsible innovation.Essays Biochem. 2016 Nov 30;60(4):347-355. doi: 10.1042/EBC20160048. Essays Biochem. 2016. PMID: 27903822 Review.
Cited by
-
A Mobilising Concept? Unpacking Academic Representations of Responsible Research and Innovation.Sci Eng Ethics. 2017 Feb;23(1):81-103. doi: 10.1007/s11948-016-9761-6. Epub 2016 Mar 8. Sci Eng Ethics. 2017. PMID: 26956121
-
"Omics"-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives.Proteomes. 2016 Sep 12;4(3):28. doi: 10.3390/proteomes4030028. Proteomes. 2016. PMID: 28248238 Free PMC article. Review.
-
Ethical, Political and Societal Implications of the Open Access Journal Movement in the Era of Economic Crisis, with Emphasis on Public Health Pharmacogenomics.Curr Pharmacogenomics Person Med. 2013 Dec;11(4):312-315. doi: 10.2174/1875692111666131126234122. Curr Pharmacogenomics Person Med. 2013. PMID: 25045411 Free PMC article.
-
Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA).Curr Pharmacogenomics Person Med. 2011 Dec 1;9(4):243-251. doi: 10.2174/187569211798377153. Curr Pharmacogenomics Person Med. 2011. PMID: 22523528 Free PMC article. No abstract available.
-
Personalized Medicine in a New Genomic Era: Ethical and Legal Aspects.Sci Eng Ethics. 2017 Aug;23(4):1207-1212. doi: 10.1007/s11948-016-9828-4. Epub 2016 Nov 28. Sci Eng Ethics. 2017. PMID: 27896605
References
-
- Anderson NG, Matheson A, Anderson NL. Back to the future: the human protein index (HPI) and the agenda for post-proteomic biology. Proteomics. 2001;1:3–12. - PubMed
-
- Legrain P, Aebersold R, Archakov A, et al. The human proteome project: Current state and future direction. Mol Cell Proteomics. 2011 Apr 29; [Epub ahead of print] - PubMed
-
- Paik YK, Kim H, Lee EY, et al. Overview and introduction to clinical proteomics. Methods Mol Biol. 2008;428:1–31. - PubMed
-
- Kalow W, Ozdemir V, Tang BK, et al. The science of pharmacological variability: an essay. Clin Pharmacol Ther. 1999;66(5):445–7. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources